Universal-Investment-Luxembourg S.A. has decreased its portfolio of shares in SP Group A/S
Universal-Investment-Luxembourg has on 15 May 2023 informed SP Group A/S that they effective 9 May 2023 owns less than 5% of the share capital and voting rights of SP Group A/S and is therefore no longer major shareholder.
Universal-Investment-Luxembourg S.A. now owns 620,753 number of shares, each with a nominal value of DKK 2.00, in SP Group A/S corresponding to 4.97 % of the share capital and voting rights.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ad hoc announcement: GAM Holding AG confirms the publication of the offer prospectus of Liontrust9.6.2023 07:00:00 CEST | Press release
9 June 2023 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM Holding AG confirmsthe publication of the offer prospectus of Liontrust Liontrust Asset Management PLc had previously stated that it intended to publish a Circular and the Offer Prospectus for the public exchange offer for all publicly held registered shares of GAM Holding AG on 9 June 2023. Liontrust Asset Management PLc now expects to publish both the Circular and Offer Prospectus on or around 13 June 2023. GAM is making this announcement pursuant to its obligations under Article 53 of the Listing Rules of the SIX Exchange. For further information please contact: Charles Naylor Head of Communications and Investor Relations T +44 7890 386 699 Media Relations Ute Dehn Christen T +41 58 426 31 36 Visit us: www.gam.com Follow us: Twitter and LinkedIn GAM GAM is an independent investment manager that is listed in Switzerland and has, within its Investment Management division, AuMA of CHF 23.3 billion (£21
Mowi ASA (OSE: MOWI): 2023 Salmon Farming Industry Handbook9.6.2023 06:30:00 CEST | Press release
Please find attached the 2023 version of the Salmon Farming Industry Handbook. The handbook is also available on our website www.mowi.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2023 Salmon Farming Industry Handbook
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n